Study Of Steroid And CNI Immunosuppression Withdrawal Post-Transplant

The University of Cincinnati will lead a $5.2 million national trial studying removal of both corticosteroids and common immunosuppression treatments from the post-transplant drug regimen for kidney transplant patients. The Belatacept Early Steroid withdrawal Trial (BEST) seeks to determine if a belatacept-based regimen for post-transplant patients can prevent organ rejection without the harmful side effects posed by corticosteroids and calcineurin inhibitor (CNI) immunosuppressants. Belatacept is a modified version of the drug abatacept, which is used to treat rheumatoid arthritis...

Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/WWRrZHRpTe4/253364.php

sport sport medical sport news